z-logo
open-access-imgOpen Access
NOVEL CELLULAR STAINING PROTOCOL AND ANTIPROLIFERATIVE EFFECT OF VERNONIA AMYGDALINA DELILE ON LUNG AND PROSTATE CANCER CELLS.
Author(s) -
Clément G. Yedjou,
Solange S Tchounwou,
Kathleen Williams,
Paul B. Tchounwou
Publication year - 2018
Publication title -
zenodo (cern european organization for nuclear research)
Language(s) - English
Resource type - Journals
ISSN - 2277-9655
DOI - 10.5281/zenodo.1403369
Subject(s) - prostate cancer , propidium iodide , lung cancer , vernonia amygdalina , cancer research , cancer , medicine , cancer cell , prostate , dapi , staining , acridine orange , biology , pathology , oncology , traditional medicine , apoptosis , programmed cell death , biochemistry
There is a critical need for more effective therapeutic approaches for cancer. Vernonia amygdalina Delile (VAD) has been used in African traditional medicine for the prevention and/or treatment of several diseases including diarrhea, intestinal illnesses, and cancer. However, the effects of VAD on human lung cancer and human prostate cancer cells remain largely unknown. The aim of this study was to explore a novel cellular staining protocol using acridine orange/propidium iodide (AO/PI) and to test the antiproferative activity of VAD against human lung cancer (A-549) cells and human prostate cancer (PC-3) cells. Our studies demonstrate that VAD inhibits the proliferation of both A-549 and PC-3 cells in a dose-dependent manner. This finding suggests that VAD may be useful in lung and prostate cancer prevention. However, further research is needed to elucidate the chemopreventive effects of VAD against cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom